ATM T2666A

CI-VAR-00004300Explore in graph →ClinVar 219594 CIViC 901 rs745775382

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Lymphocytic Leukemia1
ATM T2666A	Doxorubicin	Predictive	D	Supports Resistance	3	accepted	EID2221 Primary peripheral blood mononuclear cells were taken from chronic lymphocytic leukemia patients, some of whom had prior therapy. Cells were treated with doxorubicin to induce double-strand (DSB) and … (full text at CIViC) PMID 23585524 · Navrkalova et al., 2013 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
219594	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications	1	Ataxia-telangiectasia syndrome; Hereditary cancer-predisposing syndrome; Malignant tumor of breast	germline	5	Nov 18, 2025	clinvar